WO2006109170A3 - Combination therapy for treatment of cardiovascular diseases and related conditions - Google Patents

Combination therapy for treatment of cardiovascular diseases and related conditions Download PDF

Info

Publication number
WO2006109170A3
WO2006109170A3 PCT/IB2006/000968 IB2006000968W WO2006109170A3 WO 2006109170 A3 WO2006109170 A3 WO 2006109170A3 IB 2006000968 W IB2006000968 W IB 2006000968W WO 2006109170 A3 WO2006109170 A3 WO 2006109170A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
related conditions
treatment
cardiovascular diseases
cardiovascular disease
Prior art date
Application number
PCT/IB2006/000968
Other languages
French (fr)
Other versions
WO2006109170A2 (en
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Milton Lethan Pressler
Original Assignee
Esperion Therapeutics Inc
Charles Larry Bisgaier
Roger Schofield Newton
Milton Lethan Pressler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc, Charles Larry Bisgaier, Roger Schofield Newton, Milton Lethan Pressler filed Critical Esperion Therapeutics Inc
Publication of WO2006109170A2 publication Critical patent/WO2006109170A2/en
Publication of WO2006109170A3 publication Critical patent/WO2006109170A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides combination regimens of an AIM-lipid complex, one or more statins and one or more anti-inflammatory agents for treating and preventing of cardiovascular disease and related conditions. The compositions and methods of the instant invention encompass a non-invasive combination therapy to treat cardiovascular disease and related conditions. Pharmaceutical compositions of the combination therapy are also provided.
PCT/IB2006/000968 2005-04-14 2006-04-03 Combination therapy for treatment of cardiovascular diseases and related conditions WO2006109170A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67127405P 2005-04-14 2005-04-14
US60/671,274 2005-04-14

Publications (2)

Publication Number Publication Date
WO2006109170A2 WO2006109170A2 (en) 2006-10-19
WO2006109170A3 true WO2006109170A3 (en) 2007-04-19

Family

ID=36688047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000968 WO2006109170A2 (en) 2005-04-14 2006-04-03 Combination therapy for treatment of cardiovascular diseases and related conditions

Country Status (1)

Country Link
WO (1) WO2006109170A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007283A (en) * 2007-06-15 2009-02-18 World Trade Imp Export Wtie Ag Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent.
WO2011094431A1 (en) * 2010-01-28 2011-08-04 Psivida Us, Inc. Sustained-release nsaid/hmg coa reductase inhibitor compositions
EP3060649A4 (en) 2013-10-23 2017-07-12 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Reprogramming cardiomyocytes with one transcription factor
KR20190037195A (en) * 2016-03-30 2019-04-05 더 제이. 데이비드 글래드스톤 인스티튜트, 어 테스터멘터리 트러스트 이스타빌리쉬드 언더 더 윌 오브 제이. 데이비드 글래드스톤 Enhanced direct cardiac reprogramming
EP3579827A4 (en) * 2017-02-08 2021-01-06 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity
WO2004106486A2 (en) * 2003-05-27 2004-12-09 Vascular Biogenics Ltd. Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
EP1495756A1 (en) * 2002-04-08 2005-01-12 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1495756A1 (en) * 2002-04-08 2005-01-12 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent
WO2004106486A2 (en) * 2003-05-27 2004-12-09 Vascular Biogenics Ltd. Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders
US20040204756A1 (en) * 2004-02-11 2004-10-14 Diaz Stephen Hunter Absorbent article with improved liquid acquisition capacity

Also Published As

Publication number Publication date
WO2006109170A2 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
MY147247A (en) Organic compounds and their uses
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
NO20072167L (en) Combination comprising ZD6474 and an antiandrogen
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2008089070A3 (en) Combination therapy for the treatment of cancer
WO2006109170A3 (en) Combination therapy for treatment of cardiovascular diseases and related conditions
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2010065563A3 (en) Apratoxin therapeutic agents: mechanism and methods of treatment
WO2008057313A3 (en) Methods of using e2f2 for the treatment of hypertension

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC FORM 1205A SENT 27.12.07

122 Ep: pct application non-entry in european phase

Ref document number: 06727526

Country of ref document: EP

Kind code of ref document: A2